Search results for "Medicaments"

showing 10 items of 43 documents

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

2018

ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…

0301 basic medicinemedicine.medical_specialtyTime to relapseRelapse rateGastroenterologyAssaigs clínics de medicaments03 medical and health sciencesMalalties del sistema nerviós0302 clinical medicineimmune system diseasesInternal medicineMedicineIn patientRelapse riskAdverse effectSurvival analysisbusiness.industryGeneral NeuroscienceNervous system DiseasesDrug testingmedicine.diseaseMyasthenia gravis030104 developmental biologyRituximabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

The Effects of N-Acetylcysteine on the Rat Mesocorticolimbic Pathway: Role of mGluR5 Receptors and Interaction with Ethanol

2021

N-acetylcysteine (NAC) is a prodrug that is marketed as a mucolytic agent and used for the treatment of acetaminophen overdose. Over the last few decades, evidence has been gathered that suggests the potential use of NAC as a new pharmacotherapy for alcohol use disorder (AUD), although its mechanism of action is already being debated. In this paper, we set out to assess both the potential involvement of the glutamate metabotropic receptors (mGluR) in the possible dual effect of NAC administered at two different doses and NAC’s effect on ethanol-induced activation. To this aim, 30 or 120 mg/kg of NAC was intraperitoneally administered to rats with the presence or absence of the negative allo…

0301 basic medicinePharmaceutical ScienceglutamatePharmacologyAcetylcysteine03 medical and health sciencesPharmacy and materia medica0302 clinical medicineNeurochemicalDrug Discoverymental disordersmedicinealcoholismMetabotropic glutamate receptor 5ChemistryCommunicationRGlutamate receptor<i>N</i>-acetylcysteineN-acetylcysteineRS1-441030104 developmental biologyMetabotropic receptorMTEPMechanism of actionMetabotropic glutamate receptorAlcoholismeMedicineMolecular Medicinemedicine.symptomTecnologia farmacèuticaMedicaments030217 neurology & neurosurgerymedicine.drugPharmaceuticals
researchProduct

Certamen pharmaceutico-galenicum, in quo tres continentur dissertationes, circa theriacae magnae praestantiam / Auctore Josepho Arnau, in Uniuersitat…

1727

Port. amb orla tip. Banda, caplletra ornada Sign.: A-L4, M3 Text amb postil·les marginals Reclams

Medicaments Composició obres anteriors a 1800
researchProduct

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019

Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. Methods Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K arra…

0301 basic medicineOncologymedicine.medical_treatmentADNlcsh:MedicineTriple Negative Breast NeoplasmsEpigenesis Genetic0302 clinical medicineGenetics (clinical)Triple-negative breast cancermedicine.diagnostic_testHigh-Throughput Nucleotide SequencingNuclear ProteinsMethylationMiddle AgedNeoadjuvant TherapyGene Expression Regulation NeoplasticTreatment OutcomeMyogenic Regulatory FactorsEfectes secundaris dels medicaments030220 oncology & carcinogenesisCohortFemaleTaxoidsMetilacióMicrotubule-Associated ProteinsAdultmedicine.medical_specialtylcsh:QH426-470MethylationMinor Histocompatibility Antigens03 medical and health sciencesBreast cancerTriple-negative breast cancerInternal medicineCell Line TumorBiopsyGeneticsmedicineHumansEpigeneticsMolecular BiologyEpigenetic signatureAgedChemotherapybusiness.industryGene Expression ProfilingResearchlcsh:RSequence Analysis DNADNADNA Methylationmedicine.diseaseHuman geneticsRepressor Proteinslcsh:Genetics030104 developmental biologyDrug side effectsbusinessPredictionDevelopmental Biology
researchProduct

Association of burning mouth syndrome with xerostomia and medicines

2005

Objetivo: Identificar factores de riesgo para el síndrome de boca ardiente (SBA) a través de estudio de casos y controles. Material y métodos: Se realizó análisis cuantitativo del flujo salival total en reposo y estimulado; se registraron la xerostomía subjetiva, el consumo de medicamentos y los estados psicológicos de ansiedad y depresión en 40 pacientes con SBA y 40 controles. Resultados: El análisis ANOVA mostró diferencias significativas en las medias del número de medicamentos/día, número de medicamentos xerostomizantes/día, xerostomía subjetiva, ansiedad y depresión, entre los grupos estudiados. No se observaron diferencias significativas en las tasas de flujo salival en reposo y esti…

medicamentosEfecte dels medicaments sobre els microorganismeshiposalivaciónOdontologíaMalalties de la boca:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludxerostomíaMouth diseasesUNESCO::CIENCIAS MÉDICASEffect of drugs on microorganismsflujo salivalSíndrome de boca ardienteSaliva
researchProduct

Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating…

2015

BACKGROUND: Despite the good safety of rivaroxaban, there is limited information on strategies for urgent reversal of its antihemostatic effects.Methods and Results:Alterations of hemostasis induced by rivaroxaban (230 ng/ml) were assessed by using several tests applied to steady and circulating human blood. Effects on thrombin generation (TG) and thromboelastometry (TEM) parameters were measured. Modifications in platelet adhesive, aggregating and procoagulant activities were evaluated in studies with circulating blood. The potential reversal of prothrombin complex concentrates (PCCs; 50 IU/kg), activated PCCs (aPCCs; 75 IU/kg), or recombinant factor VIIa (rFVIIa; 270 μg/kg) was evaluated.…

HemostàsiaPharmacologyFibrinAssaigs clínics de medicamentsRivaroxabanMedicineHumansPlateletFactor VIIIaCoagulació sanguíniaRivaroxabanHemostasisFactor VIIIbiologybusiness.industryDrugsDrug testingGeneral MedicineBlood coagulationBlood Coagulation FactorsThromboelastometryCoagulationRecombinant factor VIIaHemostasisAnesthesiabiology.proteinCardiology and Cardiovascular MedicinebusinessPerfusionMedicamentsmedicine.drugCirculation journal : official journal of the Japanese Circulation Society
researchProduct

Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2019

The Collaborative Working Group “Noma Project Team”.

0301 basic medicinelcsh:Immunologic diseases. Allergycritical limb ischemiaCell typecost-effectivecell-based therapyImmunologyBioinformaticsCell therapy03 medical and health sciences0302 clinical medicineImmunology and AllergyMedicineOriginal Researchclinical trialsdiabetesbusiness.industryMesenchymal stem cellType 2 Diabetes MellitusCritical limb ischemiacellular medicamentsClinical trial030104 developmental biologyStem cellmedicine.symptombusinesslcsh:RC581-607030215 immunologyAdult stem cell
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Sentir del doctor Manuel Marti en orden a la composicion de los trociscos de vivora, uno de los ingredientes de la teriaca magna

1727

Marca a la portada Signatures: A14 Text a una columna a 40 línies Port. dins orla, alg. orn. a l'inici i a la fi del text

Medicaments Composició Obres anteriors al 1800. lemac
researchProduct

Documento de consenso sobre el tratamiento antimicrobiano de las infecciones bacterianas odontogénicas

2005

Las infecciones de la cavidad bucal son un problema de salud pública frecuente y motivo constante de prescripción antibiótica; el 10% de los antibióticos se emplean para tratar este problema. Sin embargo, hasta la fecha son pocos los estudios realizados para determinar su incidencia. Asímismo, su relación con ciertas enfermedades sistémicas (cardiacas, endocrinas, etc...) confiere a estas patologías una importancia vital. A pesar de la reconocida frecuencia e importancia de las infecciones odontogénicas, llama la atención la actual dispersión de criterio en varios aspectos referentes a su clasificación, terminología y recomendaciones terapéuticas. El objetivo principal de este documento, re…

MicroorganismosEfecte dels medicaments sobre els microorganismes:CIENCIAS MÉDICAS ::Ciencias clínicas::Otras [UNESCO]Bacterial diseasesMicroorganismsAntibiòticsOral medicineMicroorganismesMouth MicrobiologyClasificaciónMalalties de la bocaInfectionsAmoxicilina/ácido clavulánicoAntibioticsResistenciaTratamientoMicrobiologia dentalOdontogénicosAntibióticosInfecciones odontogénicas; Clasificación; Diagnóstico; Tratamiento; Microorganismos; Odontogénicos; Resistencia; Antimicrobianos; Antibióticos; Amoxicilina/ácido clavulánicoGeneral DentistryAntimicrobianosMouthMalalties bacterianesUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::OtrasBocaDiagnósticoInfecciones odontogénicasInfeccionsMouth diseasesOtorhinolaryngologyEstomatologiaEffect of drugs on microorganisms
researchProduct